HAE

Haemonetics Corporation (HAE) - Q1 2026 Summary

Business Context and Reporting Period

This summary covers Haemonetics Corporation's Form 10-Q for the quarterly period ended June 28, 2025 (Fiscal Q1 2026). Haemonetics is a global medical technology company operating in three segments: Plasma (collection devices and software), Blood Center (blood collection and processing), and Hospital (Interventional Technologies and Blood Management Technologies). The company is a large accelerated filer with 48.16 million shares of common stock outstanding as of June 28, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 4.4% year-over-year. This was driven by a 21.7% drop in the Blood Center segment (due to the divestiture of the Whole Blood product line) and a 4.4% decline in the Plasma segment (due to the CSL customer transition). These declines were partially offset by a 4.2% increase in the Hospital segment.
• Margin Expansion: Despite lower revenue, Gross Margin expanded significantly from 52.0% to 59.8%, and Operating Margin improved from 11.8% to 16.8%. This was primarily due to pricing benefits, favorable product mix, reduced restructuring costs, and lower amortization of fair value inventory step-up.
• Net Income Decrease: Net income fell 11.3% to $34.0 million. The decrease was largely due to the absence of a $12.6 million gain on the repurchase of convertible notes recorded in the prior year and a higher effective tax rate (24.7% vs. 17.9%) due to the lack of stock compensation windfall benefits.
• Cash Flow Improvement: Operating cash flow turned positive at $17.4 million, a $44.8 million improvement over the prior year's outflow of $27.4 million, driven by working capital management and the absence of large non-cash adjustments related to prior-year gains.

Guidance, Outlook, and Risks

• Strategic Initiatives: In May 2025, the Board approved a "Market and Regional Alignment Initiative" to improve operational performance and reduce costs, with $2.8 million in costs incurred in Q1. The company expects this to continue through fiscal 2027.
• Capital Allocation: In April 2025, the Board authorized a new $500 million share repurchase program through April 2028. The company completed a $150 million accelerated share repurchase in April 2025.
• Divestiture: The company completed the sale of its Whole Blood product line to GVS in January 2025 for $43.3 million upfront cash plus contingent consideration.
• Legal Proceedings: The company is involved in patent litigation with Philips (regarding OpSens technology) and has filed suits against Terumo BCT and Fresenius Kabi regarding blood plasma collection patents. Management believes it has meritorious defenses and that outcomes are uncertain.
• Tax Legislation: The company is assessing the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 on its consolidated financial statements.

Investor Verification Checklist

• CSL Transition Impact: Verify the timeline and financial impact of the CSL Plasma customer transition, as the company expects no North America disposable sales to CSL in fiscal 2026.
• Whole Blood Divestiture: Confirm the status of the Transition Services Agreement (TSA) and Contract Manufacturing Agreement (CMA) with GVS to understand ongoing revenue streams from the divested unit.
• Debt Maturities: Review the $300 million principal balance of the 2026 Convertible Notes maturing in March 2026 and the company's liquidity position to ensure repayment or refinancing capability.
• Restructuring Costs: Monitor the "Market and Regional Alignment Initiative" for actual cost savings versus the estimated $3.4 million incurred to date.
• Patent Litigation: Track the progress of lawsuits against Terumo BCT and Fresenius Kabi, as well as the defense against Philips, for potential financial liabilities or strategic advantages.